It’s funny how you barely think about healthcare companies until you actually need them. And what we would all want to see at such times is a simple, smooth checkup and the quiet efficiency.
Not long ago, though, Wall Street was worried about UnitedHealth (UNH), with rising costs and pressure on margins weighing on sentiment. Then came the first-quarter 2026 earnings report, shifting the narrative and prompting Morgan Stanley to raise its price target. To me, it feels less like a bold call and more like the market is catching up to a strength that never really left.
UnitedHealth Group (UNH) didn’t just beat expectations on April 22, 2026. It beat them in the places that mattered most. Just exactly where investors were looking. Shares ended the day up 7%. That’s one of the clearest single-session signals that a turnaround story is beginning to find its footing.
“We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency, and connectivity,” said UNH CEO Stephen Hemsley.
“The print represents a strong start to ’26 and sets a positive tone for MCOs. We expect
momentum can continue as UNH continues to execute and build credibility. Reiterate Top Pick.” Morgan Stanley said.
Morgan Stanley raises UNH stock target after strong earnings
Morgan Stanley moved quickly after earnings, raising its price target on UnitedHealth Group (UNH) from $375 to $395, while maintaining its “Overweight” rating and Top Pick status.
The move followed a stronger-than-expected first-quarter performance that shifted investor sentiment.
UnitedHealth Group’s Q126 earnings release results:
- First-quarter 2026 revenues of $111.7 billion, up from $109.6 billion in the year-ago quarter (up 2%)
- Earnings of $6.90 per share; adjusted earnings of $7.23 per share
- Medical care ratio of 83.9%, down from 84.8% in Q1 2025
- Cash flows from operations of $8.9 billion, or 1.4 times net income
- Full-year 2026 EPS guidance raised to $18.27 per share from $17.77
- 2027 EPS: $20.95 (from $20.45)
Source: UnitedHealth Group First Quarter 2026 Results
Shares rose about 7% following the report, reflecting renewed confidence in the company’s recovery story.
The medical loss ratio improvement is the number that matters most to managed care investors, and UNH delivered it. Per Morgan Stanley’s note, the favorable ratio was aided in part by prior-year development and a softer flu season. Meaning the second quarter, with full claims data visibility, will provide a cleaner read on the underlying cost trend by product.
Related: Morgan Stanley names UnitedHealth a “Top Pick”
Optum Health was the other critical proof point. The division’s first-quarter EBIT handily beat expectations, according to Morgan Stanley, offering early evidence that operational investments made in the second half of 2025 are beginning to convert into measurable results.
Clinical reviews increased 50% in UNH’s West region, and skilled nursing admissions fell 35% year over year in the first month of the new care navigation approach, according to the MS’s note.
Morgan Stanley says UNH is clearly moving in the right direction
Morgan Stanley sees this as a key differentiator. In its first-quarter update, the company outlined a clear strategy. To deploy AI across administrative and clinical operations with an expected 2:1 financial return, and many programs paying back within 12 to 18 months. According to MS, the near-term ROI stands out in healthcare, where tech investments often take years to show results.
Several initiatives are already delivering impact. Avery, a generative AI chatbot for UnitedHealthcare members, is reducing administrative friction and improving user experience. Optum Real, an AI-driven claims platform, is cutting manual adjudication costs by 76%, according to MS note.
Related: Morgan Stanley adjusts RTX price target after earnings
Ambient AI is helping physicians and nurses automate clinical documentation at scale, while AI-enabled self-service at Optum Rx has reduced call center volumes by 25%, MS’s note confirms.
All internal AI development is being funneled through Optum Insight, building a proprietary pipeline that UNH plans to commercialize externally. Morgan Stanley views this untapped AI potential as a meaningful upside not yet reflected in consensus estimates, with an investor day in the second half of 2026 seen as a possible catalyst.
Morgan Stanley’s UNH target and 2027 earnings reveal something
Morgan Stanley’s revised price target of $395, up from $375, is grounded in a sum-of-the-parts analysis that values each of UNH’s major business segments separately against comparable peer multiples, according to the firm’s note.
Morgan Stanley revised UNH’s earnings estimates as follows:
- 2026 adjusted EPS estimate raised to $18.27 from $17.77
- 2027 adjusted EPS estimate raised to $20.95 from $20.45
- Price target of $395 implies 18.9 times the firm’s 2027 EPS estimate
Even after the 7% single-session move, UNH shares were trading at just 13.7 times Morgan Stanley’s 2028 EPS estimate of $25.34. Well below the stock’s five-year and ten-year historical forward price-to-earnings averages of 15.8 times and 15.2 times, respectively, according to Morgan Stanley.
The more aggressive scenario in Morgan Stanley’s illustrative 2027 earnings bridge points to potential upside of 22% to the bank’s own estimates and 27% to consensus, if management executes against its stated margin targets, yielding a broad illustrative 2027 EPS range of $21.10 to $25.63, per the firm. That range doesn’t incorporate incremental AI-driven savings that could materialize on top.
More Health Care:
- If your Medicare plan was canceled, do this now
- Health care costs are the wild card in year-end tax planning
- 22 million Americans hit by ACA health insurance cliff after vote fails
Management also reiterated confidence in its long-term margin targets across key segments, according to Morgan Stanley’s note, including Optum Health margins of 6% to 8%, Medicare Advantage improvement toward the high end of the 2% to 4% target range in 2027, and modest Medicaid margin improvements beginning next year.
For you who have been waiting for evidence that the UNH recovery is more than narrative, the first quarter of 2026 just provided it.
Related: UNH stock just did something to the Dow Jones you rarely see